BioVie Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.7M
- Price
- $1.95
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.84%
- Volume
- 19.8M
About
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Quick stats
Shares outstanding7.5M
Computed float7.1M
Float / shares94.3%
Cash runway (months)2.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001580149
Websitehttps://bioviepharma.com
AI Summary
AI-generated1/23
standardbullishother
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
BioVie CEO Cuong Do will appear on the RedChip Small Stocks, Big Money show to discuss topline results from the Company's Phase 2 clinical trial evaluating bezisterim in Parkinson's disease.
Do reported statistically significant improvements versus placebo across measures of motor and non-motor symptoms, along with biomarker findings supporting potential impacts on neuroinflammation.
The interview also covers the company's fully enrolled 200-patient long COVID trial, which is supported by a $13 million grant and targets topline data readout after Labor Day.